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background: Reactive oxygen species (ROS) burden is increased in heart failure (HF) and can lead to damage of cellular DNA, lipids, and 
proteins and ultimately to cell death. We showed that long-term therapy with Bendavia (BEN), a novel mitochondria targeting peptide, improves 
mitochondria and LV function in dogs with HF. This study examined the effects of BEN on ROS burden in plasma and LV myocardium of dogs with 
microembolization-induced HF (LV ejection fraction ~30%).
Methods: HF dogs (n=14) were randomized to 3 months therapy with subcutaneous injections of BEN (0.5 mg/kg once daily, n=7) or saline 
(control, n=7). Plasma was obtained at baseline (BL), after induction of HF (pre-treatment, PRE) and at 6 weeks (Wks) and 12-Wks of therapy. 
LV tissue was obtained after 12-Wks of therapy and from 6 normal (NL) dogs for comparison. ROS levels were evaluated luminometrically and 
expressed as relative luminescence units (RLUx105/ml) in plasma and in RLUx104/μg protein in tissue.
results: Plasma ROS levels increased in both study groups at PRE compared to BL (Table). ROS levels also increased in LV of HF Controls 
compared to NL dogs (1.45 ± 0.18 vs. 0.77 ± 0.04; p<0.05). BEN decreased ROS levels in plasma at 6-Wks and more profoundly at 12-Wks (Table) 
and in LV tissue compared to Controls (0.90 ± 0.0.06 vs. 1.45 ± 0.18, p<0.05).
conclusions: Long-term therapy with BEN reduced ROS levels in plasma and LV tissue of HF dogs. Alleviating ROS burden with BEN likely 
contributed to the observed improvement of LV function in dogs with HF.
Plasma ROS Levels
BL PRE 6-Wks 12-Wks
Plasma ROS in Control Group 5.0 ± 0.3 21.1 ± 3.1* 22.9 ± 3.6* 24.7 ± 3.6*
Plasma ROS in BEN Group 5.3 ± 0.5 20.7 ± 2.6* 18.4 ± 1.8* 10.6 ± 0.8*†
*=p<0.05 vs. BL; †=p<0.05 vs. PRE
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